Symbol="FHTX"
AssetType="Common Stock"
Name="Foghorn TherapeuticsÂ Inc"
Description="Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts."
CIK="1822462"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="338781000"
EBITDA="-119281000"
PERatio="None"
PEGRatio="None"
BookValue="-0.588"
DividendPerShare="0"
DividendYield="0"
EPS="-2.62"
RevenuePerShareTTM="0.494"
ProfitMargin="0"
OperatingMarginTTM="-5.95"
ReturnOnAssetsTTM="-0.178"
ReturnOnEquityTTM="-4.704"
RevenueTTM="20617000"
GrossProfitTTM="-86390000"
DilutedEPSTTM="-2.62"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.354"
AnalystTargetPrice="15.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="17.03"
PriceToBookRatio="10.71"
EVToRevenue="2.963"
EVToEBITDA="0.568"
Beta="2.159"
num_52WeekHigh="18.12"
num_52WeekLow="4.51"
num_50DayMovingAverage="7.49"
num_200DayMovingAverage="7.07"
SharesOutstanding="41824800"
DividendDate="None"
ExDividendDate="None"
symbol="FHTX"
open="7.98"
high="8.21"
low="7.94"
price="8.10"
volume="70726.00"
latest_trading_day="2023-07-21"
previous_close="7.90"
change="0.20"
change_percent="2.5316%"
aroon_positive_momentum_days="55"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="55"
Volume_recent_avg="84184"
Change_recent_avg="0.02"
Delta_recent_avg="0.57"
Variance_recent_avg="0.29"
Change_ratio_recent_avg="0.19"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="55"
Aroon_momentum_negative="45"
image_negative_thumbnail_id_1="140"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0036.jpeg"
image_negative_thumbnail_id_2="121"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0055.jpeg"
image_neutral_thumbnail_id_1="569"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0030.jpeg"
image_neutral_thumbnail_id_2="543"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0056.jpeg"
image_positive_thumbnail_id_1="664"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0044.jpeg"
image_positive_thumbnail_id_2="663"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0045.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1167"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
